TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On January 23, 2018, Tonix Pharmaceuticals Holding Corp. (the “Company”) issued a press release announcing that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application 12/948,828, “Methods and compositions for treating symptoms associated with posttraumatic stress disorder using cyclobenzaprine,” covering the use of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets).

A copy of the press release that discusses this matter is filed as Exhibit 99.01 to, and incorporated by reference in, this report. The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing.

(d)Exhibits.

______

* Furnished herewith.

Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.01 2 s108787_ex99-01.htm EXHIBIT 99.01 Exhibit 99.01    Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)   Patent Will Provide Intellectual Property Protection until 2030 for Use of Cyclobenzaprine in the Treatment of Posttraumatic Stress Disorder (PTSD) NEW YORK,…
To view the full exhibit click here